Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study

• Published in: Annals of the rheumatic diseases Vol. 73; no. 1; pp. 124 - 131
• Main Authors: McInnes, Iain B, Kim, Ho-Youn, Lee, Sang-Heon, Mandel, David, Song, Yeong-Wook, Connell, Carol A, Luo, Zhen, Brosnan, M Julia, Zuckerman, Andrea, Zwillich, Samuel H, Bradley, John D
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.01.2014
• Subjects: Administration, Oral; Adult; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Atorvastatin; Cardiovascular Diseases - complications; Cardiovascular Diseases - drug therapy; Cholesterol; Cytokines; Disease; Double-Blind Method; Drug dosages; Drug Therapy, Combination; Family medical history; Female; Follow-Up Studies; Heptanoic Acids - administration & dosage; Heptanoic Acids - adverse effects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Lipids; Lipids - blood; Low density lipoprotein; Male; Middle Aged; Mortality; Neutrophils; Piperidines - administration & dosage; Piperidines - adverse effects; Placebos; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrroles - administration & dosage; Pyrroles - adverse effects; Rheumatoid arthritis; Studies; Treatment Outcome; Rheumatoid Arthritis; Lipids; Treatment

Objectives To evaluate the efficacy and safety of atorvastatin versus placebo in modifying lipids in patients with rheumatoid arthritis (RA) receiving the oral Janus kinase inhibitor, tofacitinib. Methods A randomised, placebo controlled, multicentre phase 2 study, open-label for tofacitinib and bli...